FibroScan®
Article | 29.11.2021
Blog and news
topic :
category :
status :
Webinar | 24.11.2021
AASLD Wrap Up; Key Lessons in NAFLD NASH Diagnostic Strategies
Article | 24.11.2021
Highlights from 2021 AASLD Liver Meeting: Early Detection and Monitoring with FibroScan® Mitigates Risk of Patients Developing Fibrosis/Cirrhosis
Article | 02.11.2021
Non-Invasive Point-of-Care Exam Helps Battle Liver Disease in Individuals with Obesity
White Paper | 27.10.2021
Independent Study Shows FibroScan® Technology Offers Payers Positive Return on Investment
Article | 01.10.2021
Link Between Non-alcoholic Fatty Liver Disease, Obesity and Liver Cancer Calls for Early Detection and Monitoring
White Paper | 14.09.2021
Impact of Obesity in Nonalcoholic Fatty Liver Disease & Metabolic Syndrome
Article | 12.08.2021
New EASL Clinical Practice Guidelines Make Unprecedented Recommendation for Non-Invasive FibroScan® and Care Management
Press Release | 09.08.2021
Echosens Highlights New EASL Clinical Practice Guidelines
Article | 03.08.2021
Douglas Dieterich, M.D., discusses role of FibroScan® in the diagnoses of chronic liver disease
Article | 28.07.2021
Non-Invasive Liver Exam Identifies Asymptomatic Liver Disease, Provides Follow-Up for Hepatitis C Virus
Article | 26.07.2021
NICE Experts Endorse FibroScan®: Cost-Effective Liver Exam
Article | 26.07.2021
Lancet Study: FibroScan® Identifies Severe Fibrosis/Cirrhosis for Earlier Diagnosis
Article | 23.07.2021
Population-Based Return on Investment of Deploying Transient Elastography
Article | 09.07.2021